Aditxt (NASDAQ: ADTX), a company dedicated to discovering, developing and deploying promising health innovations, and Evofem Biosciences Inc., a health pioneer commercializing innovative products to address unmet needs in women’s sexual and reproductive health, today announced the signing of the Second Amendment to the Amended and Restated Agreement and Plan of Merger, under which Aditxt plans to acquire Evofem. Under the Second Amendment, Aditxt and Evofem have agreed to extend the deadlines for Aditxt to complete the remaining $3 million in funding to Evofem by purchasing 3,000 shares of Evofem’s F-1 Preferred Stock. The acquisition is expected to close in the fourth quarter of 2024.
“The alliance between Evofem and Aditxt is underpinned by a shared belief in the need for innovation in women’s healthcare,” said Saundra Pelletier, CEO of Evofem. “For too long, big Pharma has invested in ‘me too’ products in already crowded categories that offer no new benefits for women. With the support and vision of Aditxt, Evofem will continue to elevate the quality of life for women by offering products that are better and positively impact the daily lives of women who must care for so many.”
To view the full press release, visit https://ibn.fm/HPaYt
About Aditxt Inc.
Aditxt is focused on discovering, developing and deploying promising health innovations. Aditxt’s diverse portfolio includes Adimune(TM), developing a new class of therapeutics designed to retrain the immune system to address organ rejection, autoimmunity and allergies; Adivir(TM), focused on identifying, developing and commercializing new ways to treat infectious diseases; and Pearsanta(TM), offering timely, convenient and high-quality personalized lab testing anytime and anywhere, backed by its CLIA-certified and CAP-accredited monitoring center. For more information, visit the company’s website at www.Aditxt.com.
NOTE TO INVESTORS: The latest news and updates relating to ADTX are available in the company’s newsroom at https://ibn.fm/ADTX
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN
